Characteristics of Multidrug Resistance in Human Tumors
Characteristics of Multidrug Resistance in Human Tumors
批准号:
7232015
负责人:
WILLIAM T BECK
金额:
$26.41万
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-09-30 至 2011-03-31
关键词:
ATP-Binding Cassette TransportersAffectAntineoplastic AgentsCell physiologyCharacteristicsClassComplementComplexCytotoxic agentDissectionDrug resistanceEnzymesEstrogensFundingGoalsHumanKnowledgeLaboratoriesLearningMediatingMediator of activation proteinMethodsModificationMolecularMulti-Drug ResistanceMutationOncologistPharmaceutical PreparationsPhenotypePlayPost-Translational Protein ProcessingProteinsRNA SplicingRegulationResearch PersonnelResistanceRoleSignal PathwaySignaling MoleculeTestingTopoisomeraseVariantWorkcancer geneticscytotoxicityinsightmemberneoplastic cellnotch proteinnovelnovel therapeuticsprotein expressionresponsetumor
中文摘要
描述(由申请人提供):尽管癌症遗传学和治疗取得了进展,但抗癌药物耐药性仍然是肿瘤学家和研究人员面临的一个巨大问题和挑战。该项目的长期目标是解剖肿瘤多药耐药的机制。以前已知,细胞水平上的抗癌药物耐药性,即使是对单一药物的耐药性,也是一种多因素现象;在选择对任何特定细胞毒性药物具有耐药性的肿瘤细胞中可能发生多种遗传变化。补充这一观点,我们最近已经了解到,抗癌药物的假定目标和介质的行动发挥复杂的作用,在细胞生理学和药物反应。例如,拓扑异构酶响应于药物治疗而经历翻译后修饰,并且这些修饰已经揭示了涉及类小泛素化的复杂信号传导途径,其也参与药物应答。此外,关于ABC转运蛋白,介导多药耐药性,我们已经了解到,这类的一个成员,MRP 1/ABCC 1,似乎是由信号分子Notch-1调节,另一个成员,BCRP/ABCG 2,是由雌激素调节。因此,研究ABC蛋白表达调控的新机制可能提供独特的方法来规避耐药性。因此,扩大我们在ABC转运蛋白和拓扑异构酶的实验室工作的历史重点,我们希望建立在过去几年的新知识和我们在以前的资助期间取得的进展,以测试的假设,拓扑异构酶和ABC蛋白质的表达的新的监管机制影响抗癌药物的反应,并提供新的治疗模式的见解。在前期研究的基础上,我提出了一个集中的应用,并提出了以下具体目标来验证我们的假设:(1)确定哺乳动物肿瘤中拓扑异构酶的调节分子机制以及通过这些酶介导的药物介导的细胞毒性;(2)确定Ubc 9和蛋白质类小泛素化在抗癌药物反应中的作用;(3)明确Notch-1调控ABC转运蛋白MRP 1/ABCC 1表达的分子机制。
英文摘要
DESCRIPTION (provided by applicant): Despite advances in cancer genetics and treatment, anticancer drug resistance remains a formidable problem and challenge to oncologists and researchers alike. The long-term goal of this project has been the dissection of mechanisms of tumor multidrug resistance. It was known previously that anticancer drug resistance at the cellular level, even to a single agent, is a multifactor phenomenon; multiple genetic changes can occur in a tumor cell selected for resistance to any particular cytotoxic agent. Complementing this view, we have learned more recently that the putative targets of anticancer agents and mediators of their actions play complex roles in cellular physiology and drug responsiveness. For example, topoisomerases undergo post- translational modifications in response to drug treatments, and these modifications have revealed a complex signaling pathway involving sumoylation that is also involved in drug responses. Further, with regard to ABC transporters, which mediate multidrug resistance, we have learned that one member of this class, MRP1/ABCC1, appears to be regulated by the signaling molecule Notch-1, and that another member, BCRP/ABCG2, is regulated by estrogen. Accordingly, study of novel mechanisms of regulation of ABC protein expression may afford unique methods to circumvent drug resistance. Thus, expanding on the historical focus of our laboratory efforts in ABC transporters and topoisomerases, we wish to build on the new knowledge of the past few years and on the progress we have made in the prior funding period to test the hypothesis that novel regulatory mechanisms for expression of topoisomerases and ABC proteins affect anticancer drug responses and offer insights into new therapeutic paradigms. Building on work done in the prior funding period, I offer here a focused application and propose the following specific aims to test our hypothesis: (1) Define the molecular mechanisms of regulation of topoisomerases in mammalian tumors and drug-mediated cytotoxicity through these enzymes; (2) Define the role of Ubc9 and protein sumoylation in anticancer drug responsiveness; and (3) Define the molecular mechanisms of novel regulation by Notch-1 of expression of the ABC transporter, MRP1/ABCC1.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Splicing factors as therapeutic targets for the treatment of ovarian cancer
-
批准号:8053431
-
项目类别:
-
资助金额:$30.4万
-
财政年份:2009
-
负责人:WILLIAM T BECK
-
依托单位:
Splicing factors as therapeutic targets for the treatment of ovarian cancer
-
批准号:7634178
-
项目类别:
-
资助金额:$31.41万
-
财政年份:2009
-
负责人:WILLIAM T BECK
-
依托单位:
Splicing factors as therapeutic targets for the treatment of ovarian cancer
-
批准号:8232122
-
项目类别:
-
资助金额:$30.78万
-
财政年份:2009
-
负责人:WILLIAM T BECK
-
依托单位:
Functions of MRP2 and MRP3 in Drug Disposition
-
批准号:7905820
-
项目类别:
-
资助金额:$0.54万
-
财政年份:2006
-
负责人:WILLIAM T BECK
-
依托单位:
CHARACTERISTICS OF MULTIDRUG RESISTANCE IN HUMAN TUMORS
-
批准号:6613759
-
项目类别:
-
资助金额:$27.95万
-
财政年份:1996
-
负责人:WILLIAM T BECK
-
依托单位:
Characteristics of Multidrug Resistance in Human Tumors
-
批准号:7097534
-
项目类别:
-
资助金额:$28.01万
-
财政年份:1996
-
负责人:WILLIAM T BECK
-
依托单位:
Characteristics of Multidrug Resistance in Human Tumors
-
批准号:7407570
-
项目类别:
-
资助金额:$26.13万
-
财政年份:1996
-
负责人:WILLIAM T BECK
-
依托单位:
CHARACTERISTICS OF MULTIDRUG RESISTANCE IN HUMAN TUMORS
-
批准号:6533118
-
项目类别:
-
资助金额:$27.95万
-
财政年份:1996
-
负责人:WILLIAM T BECK
-
依托单位:
CHARACTERISTICS OF MULTIDRUG RESISTANCE IN HUMAN TUMORS
-
批准号:6375734
-
项目类别:
-
资助金额:$27.95万
-
财政年份:1996
-
负责人:WILLIAM T BECK
-
依托单位:
CHARACTERISTICS OF MULTIDRUG RESISTANCE IN HUMAN TUMORS
-
批准号:6190160
-
项目类别:
-
资助金额:$27.95万
-
财政年份:1996
-
负责人:WILLIAM T BECK
-
依托单位:
CHARACTERISTICS OF MULTIDRUG RESISTANCE IN HUMAN TUMORS
-
批准号:2007519
-
项目类别:
-
资助金额:$26.56万
-
财政年份:1996
-
负责人:WILLIAM T BECK
-
依托单位:
CHARACTERISTICS OF MULTIDRUG RESISTANCE IN HUMAN TUMORS
-
批准号:2894646
-
项目类别:
-
资助金额:$28.39万
-
财政年份:1996
-
负责人:WILLIAM T BECK
-
依托单位:
Characteristics of Multidrug Resistance in Human Tumors
-
批准号:7786989
-
项目类别:
-
资助金额:$26.13万
-
财政年份:1996
-
负责人:WILLIAM T BECK
-
依托单位:
Characteristics of Multidrug Resistance in Human Tumors
-
批准号:7586813
-
项目类别:
-
资助金额:$26.13万
-
财政年份:1996
-
负责人:WILLIAM T BECK
-
依托单位:
CHARACTERISTICS OF MULTIDRUG RESISTANCE IN HUMAN TUMORS
-
批准号:2748702
-
项目类别:
-
资助金额:$27.38万
-
财政年份:1996
-
负责人:WILLIAM T BECK
-
依托单位:
CHARACTERISTICS OF MULTIDRUG RESISTANCE IN HUMAN TUMORS
-
批准号:2458040
-
项目类别:
-
资助金额:$26.41万
-
财政年份:1996
-
负责人:WILLIAM T BECK
-
依托单位:
ALTERED TOPOISOMERASE IN ATYPICAL MULTIDRUG RESISTANCE
-
批准号:3191769
-
项目类别:
-
资助金额:$13.05万
-
财政年份:1989
-
负责人:WILLIAM T BECK
-
依托单位:
ALTERED TOPOISOMERASE IN ATYPICAL MULTIDRUG RESISTANCE
-
批准号:3191766
-
项目类别:
-
资助金额:$13.85万
-
财政年份:1989
-
负责人:WILLIAM T BECK
-
依托单位:
ALTERED TOPOISOMERASE IN ATYPICAL MULTIDRUG RESISTANCE
-
批准号:3191768
-
项目类别:
-
资助金额:$12.75万
-
财政年份:1989
-
负责人:WILLIAM T BECK
-
依托单位:
MICRODETECTION ASSAY FOR DRUG-RESISTANT TUMORS
-
批准号:3169060
-
项目类别:
-
资助金额:$20.08万
-
财政年份:1987
-
负责人:WILLIAM T BECK
-
依托单位:
海外基金